Boston Scientific Says Epic Stent Continues Positive Clinical Outcomes

Boston Scientific Corporation

reports clinical endpoint data from the PLATINUM Long Lesion trial, demonstrating positive outcomes for the PROMUS Element™ Everolimus-Eluting Platinum Chromium (PtCr) Stent System in patients with long coronary lesions.  Results were presented today by Paul S. Teirstein, M.D., of the Scripps Clinic in La Jolla, California, and Co-Principal Investigator of the trial, at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. "The PROMUS Element Stent achieved impressive clinical outcomes in this patient population with long lesions," said Dr. Teirstein.  "This durable polymer everolimus-based stent, built on the advanced platinum chromium platform, demonstrated low rates of revascularization while reporting no myocardial infarction or stent thrombosis at two years, and should offer physicians confidence and flexibility in treating longer lesions with a single stent."